Alagebrium bromide (ALT-711) is used as an advanced glycation end-product (AGE) crosslink breaker; it reduces AGE accumulation in the kidneys, inhibits the upregulation and translocation of protein kinase C (PKC) isoforms—particularly PKC-α—in diabetic nephropathy, attenuates the expression of vascular endothelial growth factor (VEGF) and extracellular matrix proteins (fibronectin and laminin), and is associated with reduced albuminuria.